. 2020 Apr 20;31(3):e48. doi: 10.3802/jgo.2020.31.e48

Table 3. Summary of clinical trials for PARP inhibitors.

Variables	PARP inhibitor	PARP inhibitor+VEGF inhibitor	PARP inhibitor+ICI	PARP inhibitor+ICI+VEGF inhibitor
First-line maintenance	SOLO-1 (olaparib)	PAOLA-1 (olaparib+bev)	ATHENA (rucaparib+nivolumab)^†
First-line maintenance	PRIMA (niraparib)	PAOLA-1 (olaparib+bev)	MITO-25 (rucaparib+bev)^†
First-line treatment & maintenance	VELIA (veliparib)			FIRST (niraparib+TSR042+bev)^†
				DUO-O (olaparib+durvalumab+bev)^†
				ENGOT-ov43 (olaparib+pembro±bev)^†
Recurrence maintenance, platinum sensitive	SOLO-2 (olaparib)	ICON-9 (olaparib+cediranib)^†
	NOVA (niraparib)
	ARIEL3 (rucaparib)
Recurrence treatment, platinum sensitive	SOLO-3 (olaparib)	AVANOVA-2 (niraparib+bev)	MEDIOLA (olaparib+durvalumab)^*	MEDIOLA (olaparib+durvalumab+bev)^†,‡
Recurrence treatment, platinum sensitive	QUADRA (niraparib)	NRG GY-004 (olaparib+cediranib)^†	MEDIOLA (olaparib+durvalumab)^*	MEDIOLA (olaparib+durvalumab+bev)^†,‡
Recurrence treatment, platinum resistant		NRG GY-005 (olaparib+cediranib)^†	TOPACIO (niraparib+pembrolizumab)

bev, bevacizumab; ICI, immune checkpoint inhibitor; PARP, poly(ADP-ribose) polymerase; VEGF, vascular endothelial growth factor.

^*Abstract only; ^†Ongoing study; ^‡Expansion cohort.